Camilla Simpson
Director/Miembro de la Junta en SPRUCE BIOSCIENCES, INC. .
Fortuna: - $ al 30/04/2024
Origen de la red de primer grado Camilla Simpson.
| Entidad | Tipo de entidad | Industria | |
|---|---|---|---|
| Public Company | Biotechnology | 35 | |
| Public Company | Biotechnology | 19 | |
| Unknown | 7 | ||
Aristea Therapeutics, Inc.
 Aristea Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Aristea Therapeutics, Inc. operates as a clinical-stage drug development company. It develops novel therapies to treat serious inflammatory diseases. The company was founded by James Morrison MacKay in 2018 and is headquartered in Poway, CA.
7
| Holding Company | Pharmaceuticals: Major | 7 |
Dyve Biosciences, Inc.
 Dyve Biosciences, Inc. BiotechnologyHealth Technology Dyve Biosciences, Inc. operates as a research and development company. It focuses on biotech that creates novel therapeutics using proprietary science. The company was founded by Ryan Beal and Rajit Malhotra and is headquartered in Thousand Oaks, CA.
7
| Private Company | Biotechnology | 7 |
Zehna Therapeutics, Inc.
 Zehna Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Zehna Therapeutics, Inc. develops non-bactericidal inhibitors for cardiovascular and chronic kidney diseases. The company is based in Cleveland, OH.
2
| Holding Company | Pharmaceuticals: Major | 2 |
Gráfico Empresas conectadas de segundo grado
Relaciones con varias empresas
Empresas conectadas a Camilla Simpson a través de su red personal
| Empresa | Sector | Personas relacionadas | Puesto principal |
|---|---|---|---|
| ALLERGAN, INC. | Pharmaceuticals: Major | Chief Executive Officer Corporate Officer/Principal Chief Tech/Sci/R&D Officer | |
| AMGEN INC. | Pharmaceuticals: Major | Director of Finance/CFO Chief Tech/Sci/R&D Officer Chief Tech/Sci/R&D Officer | |
| BRISTOL-MYERS SQUIBB COMPANY | Pharmaceuticals: Major | Corporate Officer/Principal Corporate Officer/Principal | |
Genentech, Inc.
 Genentech, Inc. BiotechnologyHealth Technology Genentech, Inc. develops, manufactures and markets pharmaceutical products for life-threatening medical conditions. It studies various areas including oncology, immunology, neuroscience, ophthalmic diseases, microbial pathogenesis, metabolic diseases, cardiovascular diseases, and opportunistic areas. The company was founded by Herb W. Boyer and Robert A. Swanson in 1976 and is headquartered in South San Francisco, CA. | Biotechnology | Corporate Officer/Principal Chief Operating Officer Treasurer Chief Tech/Sci/R&D Officer Corporate Officer/Principal | |
| MERCK & CO., INC. | Pharmaceuticals: Major | Sales & Marketing Corporate Officer/Principal Corporate Officer/Principal | |
Human Genome Sciences, Inc.
 Human Genome Sciences, Inc. Medical SpecialtiesHealth Technology Human Genome Sciences, Inc. is a biopharmaceutical company that exists to place new therapies into the hands of those battling serious disease. Its lead products include BENLYSTA for systemic lupus erythematosus and raxibacumab for inhalation anthrax. The firm's other products include, mapatumumab, darapladib, albiglutide, ZALBIN, HGS1036 and HGS1029. The company was founded by Alan G. Walton and William A. Haseltine in 1992 and is headquartered in Gaithersburg, MD. | Medical Specialties | Director/Board Member Director/Board Member | |
| BIOGEN INC. | Pharmaceuticals: Major | Director of Finance/CFO Chairman Corporate Officer/Principal | |
Onyx Pharmaceuticals, Inc.
 Onyx Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Onyx Pharmaceuticals, Inc. operates as a biopharmaceutical company. It engages in developing innovative therapies that target the molecular mechanisms that cause cancer. The company was founded by Frank McCormick in February 1992 and is headquartered in Thousand Oaks, CA. | Pharmaceuticals: Major | Chief Tech/Sci/R&D Officer Chief Tech/Sci/R&D Officer | |
| SANGAMO THERAPEUTICS, INC. | Biotechnology | Chief Tech/Sci/R&D Officer Chief Tech/Sci/R&D Officer | |
| HALOZYME THERAPEUTICS, INC. | Biotechnology | Chairman Chief Operating Officer | |
Biotechnology Innovation Organization
 Biotechnology Innovation Organization Miscellaneous Commercial ServicesCommercial Services Biotechnology Innovation Organization is the world's biotechnology organization, providing advocacy, business development and communications services for more than 1,200 members worldwide. BIO members are involved in the research and development of innovative healthcare, agricultural, industrial and environmental biotechnology technologies. Corporate members range from entrepreneurial companies developing a first product to Fortune 100 multinationals. also represent state and regional biotech associations, service providers to the industry and academic centers. | Miscellaneous Commercial Services | Director/Board Member Investor Relations Contact | |
| ADAMAS PHARMACEUTICALS, INC. | Pharmaceuticals: Major | Chief Operating Officer Corporate Officer/Principal Chief Tech/Sci/R&D Officer | |
| ULTRAGENYX PHARMACEUTICAL INC. | Pharmaceuticals: Major | Corporate Officer/Principal Corporate Officer/Principal | |
| HORIZON THERAPEUTICS PUBLIC LIMITED COMPANY | Pharmaceuticals: Major | Director/Board Member Corporate Officer/Principal Chief Tech/Sci/R&D Officer | |
| GSK PLC | Pharmaceuticals: Major | Corporate Officer/Principal Corporate Officer/Principal | |
Duke University
 Duke University Other Consumer ServicesConsumer Services Duke University is an academic university that offers undergraduate, graduate and professional programs. It also has publications and research services. The university was founded in 1838 and is headquartered in Durham, NC. | College/University | Undergraduate Degree Graduate Degree Undergraduate Degree Masters Business Admin | |
| Stanford University | College/University | Undergraduate Degree Masters Business Admin | |
University of Washington
 University of Washington Other Consumer ServicesConsumer Services University of Washington functions as a College/University. The company is headquartered in Seattle, WA. | College/University | Corporate Officer/Principal Corporate Officer/Principal Undergraduate Degree | |
| SILENCE THERAPEUTICS PLC | Miscellaneous Commercial Services | Director of Finance/CFO Chief Tech/Sci/R&D Officer | |
| University of Otago | College/University | Undergraduate Degree Graduate Degree | |
| University of Oxford | College/University | Doctorate Degree Corporate Officer/Principal | |
| MIRATI THERAPEUTICS | Biotechnology | Chief Operating Officer Director/Board Member | |
| University of California, Los Angeles | College/University | Undergraduate Degree Corporate Officer/Principal | |
| Massachusetts Institute of Technology | College/University | Graduate Degree Doctorate Degree Undergraduate Degree Undergraduate Degree | |
| University of California, Berkeley | College/University | Doctorate Degree Masters Business Admin | |
| The University of California, San Francisco | College/University | Doctorate Degree Doctorate Degree Doctorate Degree | |
| Indian Institute of Science | College/University | Doctorate Degree Doctorate Degree | |
| The Royal College of Physicians | College/University | Corporate Officer/Principal Graduate Degree | |
OrbiMed Advisors Private Equity
 OrbiMed Advisors Private Equity Investment ManagersFinance OrbiMed Advisors Private Equity (OrbiMed Advisors Private Equity) is a private equity and venture capital subsidiary of Orbimed Advisors LLC founded in 1993 by Samuel D. Isaly. The firm is headquartered in New York and it has additional offices in San Francisco, Mumbai, Shanghai, Herzliya, Hong Kong and London. | Investment Managers | Private Equity Investor Private Equity Investor Private Equity Analyst | |
Amplyx Pharmaceuticals, Inc.
 Amplyx Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Amplyx Pharmaceuticals, Inc. develops broad-spectrum antifungal agents for the treatment of life-threatening fungal infections. The firm's compound APX001, shows broad-spectrum activity in animal models of invasive fungal infection by common species of Candida and Aspergillus. It develops oral and injectable anti-infective drugs, including protease inhibitors and antibiotics. The company was founded by André Marquis, Mitchell W. Mutz and Gerry Crabtree in 2006 and is headquartered in San Diego, CA. | Pharmaceuticals: Major | Chief Executive Officer Director/Board Member Chief Executive Officer Chief Tech/Sci/R&D Officer | |
| Rady School of Management at UC San Diego | College/University | Masters Business Admin Masters Business Admin | |
| AUDENTES THERAPEUTICS, INC. | Biotechnology | Director/Board Member Chief Tech/Sci/R&D Officer | |
| AURINIA PHARMACEUTICALS INC. | Biotechnology | Investor Relations Contact Director/Board Member | |
| The Wharton School of the University of Pennsylvania | College/University | Masters Business Admin Masters Business Admin | |
| WILSON THERAPEUTICS AB | Pharmaceuticals: Major | Director/Board Member Chief Executive Officer Director/Board Member | |
Ziarco Group Ltd.
 Ziarco Group Ltd. Pharmaceuticals: MajorHealth Technology Ziarco Group Ltd. operates as a clinical-stage biotechnology company that develops therapeutics targeting inflammatory skin diseases. The firm engages in development of novel treatments in dermatology. The company was incorporated on March 10, 2014 and is headquartered in Canterbury, the United Kingdom. | Pharmaceuticals: Major | Chairman Director/Board Member | |
| RENEO PHARMACEUTICALS, INC. | Biotechnology | Founder Founder Founder Director/Board Member Director/Board Member Director/Board Member | |
| GRITSTONE BIO, INC. | Biotechnology | Director of Finance/CFO Chief Operating Officer | |
Glycomine, Inc.
 Glycomine, Inc. BiotechnologyHealth Technology Glycomine, Inc. engages in the development of therapeutics for diseases which have no treatment options. Its therapeutic approach is to combine replacement therapies such as substrates, enzymes, or proteins with intracellular delivery vehicles consisting of bio-nanomaterials or ligands that target the molecules to the cell interior of clinically relevant organs. It focuses on research of mannose-1-phosphate and Ngly1 enzyme replacement therapy, and observational study of GLY-000. The company was founded in 2014 by Agnes Rafalko and is headquartered in San Carlos, CA. | Biotechnology | Director/Board Member Director/Board Member Director/Board Member | |
| MIRUM PHARMACEUTICALS, INC. | Pharmaceuticals: Major | Founder Director/Board Member Founder Founder Director/Board Member | |
Maze Therapeutics, Inc.
 Maze Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Maze Therapeutics, Inc. is a is a biopharmaceutical company, which engages in the development of portfolio of therapeutic candidates for a number of genetically defined diseases. It focuses on translating genetic insights into new medicines by utilizing an approach that combines the analysis of large-scale human genetics data, cutting-edge functional genomics, and an array of drug discovery approaches. The company was founded by Mark Daly, Aaron D. Gitler, Stephen Elledge, Sekar Kathiresan, and Jonathan S. Weissman in 2018 and is headquartered in San Francisco, CA. | Miscellaneous Commercial Services | Director/Board Member Chief Tech/Sci/R&D Officer | |
Curzion Pharmaceuticals, Inc.
 Curzion Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Curzion Pharmaceuticals, Inc. operates as a pharmaceutical firm. The company is headquartered in San Diego, CA. | Pharmaceuticals: Major | Chief Executive Officer Founder | |
Anjarium Biosciences AG
 Anjarium Biosciences AG BiotechnologyHealth Technology Anjarium Biosciences AG is a Swiss company that focuses on creating a new class of non-viral gene therapies to tackle genetic diseases throughout a patient's lifetime. The company is based in Schlieren, Switzerland. The company's versatile platform leverages breakthrough science and expertise at the interface of genetic medicine, synthetic biology, and nanoparticle engineering to generate a pipeline of advanced gene therapies with unique competitive advantages over current viral-vector based gene therapies. Anjarium's investors include leading international and strategic investors such as Abingworth, Gimv, Omega Funds, Pfizer Ventures, and Surveyor Capital. The company was founded by Joël de Beer, and Stephen Yoo has been the CEO of the company since 2022. | Biotechnology | Director/Board Member Director/Board Member | |
| METAGENOMI, INC. | Pharmaceuticals: Major | Chief Tech/Sci/R&D Officer Director/Board Member | |
Sorriso Pharmaceuticals, Inc.
 Sorriso Pharmaceuticals, Inc. BiotechnologyHealth Technology Sorriso Pharmaceuticals, Inc. is an American biotechnology company that focuses on developing disease-modifying antibodies to treat inflammatory diseases. Sorriso Pharmaceuticals was founded by Ciara Kennedy, who has been the CEO since its incorporation. | Biotechnology | Chairman Chief Executive Officer | |
GRI Operations, Inc.
 GRI Operations, Inc. BiotechnologyHealth Technology GRI Bio, Inc. develops cell based therapies for fibrotic and autoimmune diseases. Its programs are GRI-0621, GRI-0124, and GRI-0803. The company was founded by Marc Hertz, Vipin Kumar, and Albert Agro and is headquartered in La Jolla, CA. | Biotechnology | Founder Founder |
Estadísticas
Internacional
| Estados Unidos | 39 |
| Reino Unido | 6 |
| Irlanda | 2 |
| Nueva Zelanda | 2 |
| India | 2 |
Sectorial
| Health Technology | 34 |
| Consumer Services | 13 |
| Commercial Services | 4 |
| Finance | 3 |
Operativa
| Director/Board Member | 345 |
| Corporate Officer/Principal | 139 |
| Independent Dir/Board Member | 109 |
| Chief Tech/Sci/R&D Officer | 73 |
| Chief Executive Officer | 55 |
Las relaciones más conectadas
| Insiders | |
|---|---|
| Michael Grey | 32 |
| William Young | 32 |
| Kathryn Falberg | 30 |
| David Pyott | 27 |
| Leonard Post | 25 |
| Dan Spiegelman | 24 |
| Tiba Aynechi | 24 |
| Dina Chaya | 23 |
| Philippe Schaison | 22 |
| Pierre LaPalme | 21 |
| Bali Muralidhar | 20 |
| Ken Bate | 19 |
| Sarah Noonberg | 17 |
| Wayne T. Pan | 17 |
| Niall O'Donnell | 17 |
- Bolsa de valores
- Insiders
- Camilla Simpson
- Conexiones Empresas
